Q-omics provides the consensus-scored TMEM128 profile across patient tissues and cancer cell-line models. TMEM128 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM128 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, TMEM128 RNA expression shows 19,294 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where TMEM128 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM128 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM128 survival associations across molecular data types. TMEM128 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM128 RNA expression–survival associations across cancer types. High TMEM128 expression shows unfavorable associations in UVM, SCLC, LGG and KIRP, but favorable associations in UCS and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM128 RNA expression.
This table summarizes TMEM128 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM128. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM128 shows lower tumor expression in LUAD, LUSC and UCEC and higher tumor expression in LIHC, STAD and BLCA. The LUAD box plot shows higher TMEM128 RNA expression in normal versus tumor tissue (log2 FC = −0.530, t-test p < 0.001).
This table shows molecular features associated with TMEM128 in patient tissues and cancer cell lines. In patient samples, TMEM128 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM128 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
